Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1998-12-16
2004-10-19
Romeo, David S. (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S858000, C435S320100
Reexamination Certificate
active
06806358
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a peptide and homologues thereof which inhibit the activity of TGF-&bgr; family growth factors in vertebrates, as well as TGF-&bgr;-like growth factors in Drosophilia. Specifically, the invention relates to a highly potent fragment of the product of the Drosophilia short gastrulation gene (Sog).
2. History of the Related Art
During vertebrate development, growth factors in the TGF-&bgr; superfamily control a number of events in tissue differentiation and morphogenesis. Included in the TGF-&bgr; superfamily are the bone morphogenic proteins, which promote the growth of new bone tissue and differentiation of osteoblasts. Examples of members of this family of BMPs are BMP-4 and BMP-7, which suppress neurogenesis during early embroynic development and are active in aspects of adult physiology.
BMP-4 has been highly conserved through evolution and has a functional and structural homologue in Drosophilia, known as Dpp. BMP-4 can substitute for Dpp in Drosophilia (Padgett, et al.,
Proc. Natl.Acad.Sci. USA
90:2905-2909 (1993)) and Dpp is active in vertebrate tissues (Sampath, et al.,
Proc. Nat.Acad.Sci. USA,
90:6004-6008 (1993)). In vertebrates, chordin is a high affinity BMP-
4
binding protein which inhibits BMP-4 and BMP-7 activity (Sasai, et al.,
Cell,
779-790 (1994)), in flies, the short gastrulation (Sog) protein inhibits Dpp activity (Francois, et al.,
Genes
&
Dev.,
8:2602-2616 (1994)). Again, chordin and Sog are functional and structural homologues (Schmidt, et al.,
Development,
121:4319-4328 (1995) and Francois, et al.,
Cell,
80:19-20 (1995)). In particular, Sog inhibits BMP-4 activity in vertebrates in a manner similar to chordin (Schmidt, et al., id.), It is highly probable that Sog inhibits the activity of other members of the TGF-&bgr; family such as BMP-7, which is also inhibited by chordin.
Abnormal activity on the part of BMP-4 has been linked to human cancer, including osteosarcoma and certain leukemias. Interestingly, over-expression of BMP-4 (which is potentiated by BMP-7) has also been shown to stimulate the onset of alopecia (male pattern baldness) in mice, perhaps due to an effect on hair follicle development. Control of such activity can have therapeutic benefit in these and other conditions related to abnormalities in the functioning of TGF-&bgr; family growth factors, especially on the part of BMP-4.
SUMMARY OF THE INVENTION
The invention provides a highly potent inhibitor of TGF-&bgr; growth factor activity, with particular impact on BMP-4. In particular, the invention identifies a fragment of the Drosophilia Sog protein which has an unexpectedly high level of Dpp inhibitory activity as compared to the intact, wild-type protein.
Based on the known homologies between Dpp and BMP-4, as well as between Sog and chordin, together with other supportive data discussed below, it is predictable that the Sog fragment of the invention (hereafter, “Super-Sog”) functions as an inhibitor of BMP-4 and BMP-7 activity in vertebrates. Surprisingly, Super-Sog has a broader scope of activity than wild-type Sog in the sense that mutant phenotypes not produced by Sog inhibition of Dpp are produced in response to Super-Sog. This phenomenon suggests that Super-Sog is more potent than Sog and/or that it affects additional receptor-ligand interactions not affected by the wild-type protein, such as those mediated by activin, a vertebrate endocrine regulator whose Drosophilia homologue mediates wing development.
The invention therefore provides Super-Sog (SEQ ID NO:1; amino acids 1-292 of Sog) and active variants thereof. Such variants include SEQ ID NO: 3, a recombinant Super-Sog peptide which includes 33 amino acids encoded by the pUAS expression vector; SEQ ID NO: 6, a Super-Sog peptide which includes a mutation (W-A) in the CR-1 sequence; and SEQ ID NO: 7, a Super-Sog peptide which terminates 5′ of the CR-1 sequence. Such variants also include Super-Sog with 5′ modifications, such as modifications to the Tolloid protease cleavage site, addition of other peptides and inclusion of additional 5′ regions of Sog (e.g., CR-2).
The invention further provides pharmaceutical compositions of Super-Sog and methods for their use. Especially, useful among the pharmaceutical compositions are those which are prepared so as to increase the bioavailability of Super-Sog in vivo by, for example, protecting the peptide against unintended proteolysis.
Methods for use of Super-Sog include its therapeutic use in arresting the development of mate pattern baldness, assisting in the treatment of cancer (e.g., osteosarcomas) and inhibiting TGF-&bgr; growth factor (e.g., BMP-4, BMP-7 and activin) mediated suppression of neurogenesis to, for example, enhance the viability of fetal nervous tissue grafts in the treatment of neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease and Huntington's Disease.
REFERENCES:
Sambrook et al. Molecular Cloning: A Laboratory Manual Second Edition vols. 1, 2 and 3. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, U.S.A. Nov., 1989, apge 11.20.*
Marques et al. Production of a DPP activity gradient in the early Drosophila embryo through the opposing actions of the SOG and TLD proteins. Cell. Oct. 31, 1997;91(3):417-26.*
Biehs, B., et al., “TheDrosophila short gastrulationgene prevents Dpp from autoactivating and suppressing neurogenesis in the neuroectoderm,”Genes & Development(1996) 10:2922-2934.
Bier, E., “Anti-Neural-Inibition: A Conserved mechanism for Neural Induction,”Cell(1997) May 30; 89:681-684.
Cork, MJ, et al., “Genetic control of cytokines. Cytokine gene polymorphisms in alopecia areata,”Dermatol ClinOct. 1996;14(4):671-678.
Danilenko DM, et al., “Growth factors and cytokines in hair follicle development and cycling: recent insights from animal models and the potentials for clinical therapy,”Mol Med TodayNov. 1996;2(11):460-467.
François, V., et al., “Dorsal-ventral patterning of theDrosophilaembryo depends on a putative negative growth factor encoded by theshort gastrulationgene,”Genes & Development(1994) 8:2602-2616.
François, V., et al., “Xenopuschordinand Drosophilashort gastrulationGenes Encode Homologous Proteins Functioning in Dorsal-Ventral Axis Formation,” Letters to the Editor,CellJan. 13, (1995); 80:19-20.
Hoffmann, R., et al., “Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone,”Acta Derm VenereolJan. (1996); 76(1):17-20.
Honda, Y., et al, “Osteogenic protein-I stimulates mRNA levels of BMP-6 and decreases mRNA levels of BMP-2 and -4 in human osteosarcoma cells,”Calcif Tissue IntMar. (1997); 60(3):297-301.
Imai, R., et al., “Effects of cytokines, anti-cancer agents and coarcinogen on DNA synthesis in hair bulb cells,”J Dermatol SciApr. 1993;5(2):73-80.
King, Le Jr, et al., “Growth factor receptors and hair loss.”J Invest DermatolMay 1991;96(5):79S.
Konig, A., et al., “IFN-gamma-induced HLA-DR but not ICAM-1 expression on cultured dermal papilla cells is downregulated by TNF-alpha,”Arch Dermatol ResJul 1997; 289(8): 466-470.
Kweon, Y., et al., “TheDrosophila decapentaplegicandshort gastrulationgenes function antagonistically during adult wing vein development,”Development(1996) 122:4033-4044.
Murillas, R., et al., “Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure.”EMBO JNov. 1, 1995;14(21):5216-5223.
Nishitoh H., et al., “Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5,”J Biol ChemAug. 30, (1996); 271(35):21345-21352.
Philpott, MP, et al., “Cultured human hair follicles and growth factors,”J Invest DermatolMay 1995;104(5 Suppl)44S-45S.
Phippard, DJ, et al., “Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development,”DevelopmentSep. (1996); 122(9):2729-2737.
Sanchez-Carpintero, et al., “
Bier Ethan
Yu Kweon
Foley & Lardner
Romeo David S.
Taylor Stacy L.
University of California San Diego
LandOfFree
Peptide inhibitor of TGF-&bgr; growth factors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide inhibitor of TGF-&bgr; growth factors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitor of TGF-&bgr; growth factors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3325556